Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
20.56
-0.78 (-3.66%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines.

The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A.

is a subsidiary of Stevanato Holding S.R.L.

Stevanato Group S.p.A.
Stevanato Group logo
Country Italy
Founded 1949
IPO Date Jul 16, 2021
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 5,634
CEO Franco Stevanato

Contact Details

Address:
Via Molinella, 17
Piombino Dese, PD 35017
Italy
Phone 39 04 99 31 811
Website stevanatogroup.com

Stock Details

Ticker Symbol STVN
Exchange NYSE
Fiscal Year January - December
Reporting Currency EUR
IPO Price $21.00
CIK Code 0001849853
CUSIP Number T9224W109
ISIN Number IT0005452658
SIC Code 3841

Key Executives

Name Position
Franco Stevanato Chief Executive Officer and Executive Chairman
Marco Dal Lago Chief Financial Officer
Ugo Gay Chief Operations Officer
Lisa Miles Chief Communication Officer and Senior Vice President of Investor Relations
Paolo De Fabritiis Chief Human Resources Officer
Mauro Stocchi Chief Business Officer
Riccardo Butta President of Americas

Latest SEC Filings

Date Type Title
Nov 14, 2024 SCHEDULE 13G Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 6-K Report of foreign issuer
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SCHEDULE 13G Filing
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 5, 2024 6-K Report of foreign issuer
Nov 5, 2024 6-K Report of foreign issuer
Nov 5, 2024 6-K Report of foreign issuer